Effect Of GW501516X On How The Heart Obtains And Uses Energy

Terminated

• Conditions: Dyslipidaemias; Heart Failure

• Registration Number: NCT00318617
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, including levels of certain lipids (fats) and proteins in your blood. The data from this study may help researchers better understand the actions of this drug in the body and if this drug may be useful to treat patients with heart disease.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2005-12
• Study First Submitted: 2006-04-25
• Study First Submitted QC: 2006-04-25
• Study First Posted: 2006-04-27
• Status Verified: 2011-02
• Last Update Submitted: 2012-03-15
• Last Update Posted: 2012-03-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Energy-related chemicals and heart contraction, determined by MRI measurement of the heart.

Secondary Outcome Measures

Name	Time	Method
Additional energy-related chemicals, determined by MRI measurement of the heart. Blood proteins. Safety of GW501516X.

Trial Locations

Locations (1)

GSK Investigational Site; 🇺🇸 Philadelphia, Pennsylvania, United States